Quarterly report pursuant to Section 13 or 15(d)

Liquidity (Details Narrative)

v3.20.1
Liquidity (Details Narrative) - USD ($)
1 Months Ended 2 Months Ended 3 Months Ended
May 01, 2020
Apr. 21, 2020
Jan. 31, 2020
Sep. 30, 2019
Nov. 30, 2018
May 31, 2020
Mar. 31, 2020
Mar. 31, 2019
Jun. 17, 2020
Dec. 31, 2019
Nov. 30, 2019
Jul. 31, 2019
Cash and cash equivalents             $ 13,370,000     $ 2,321,000    
Accounts receivable, net             9,799,000     10,197,000    
Total current assets             28,145,000     16,369,000    
Total current liabilities             15,726,000     17,298,000    
Net loss             6,263,000 $ 3,419,000        
Net cash used in operating activities             7,122,000 $ 2,960,000        
Line of credit facility             1,200,000     $ 3,000,000    
Line of credit facility, remaining borrowing capacity             2,200,000          
Public offering generating net proceeds             $ 200,000          
Sale of common stock             97,817          
Subsequent Event [Member]                        
Cash                 $ 16,200,000      
Silicon Valley Bank [Member]                        
Line of credit facility         $ 850,000              
Line of credit facility, remaining borrowing capacity             $ 2,550,000          
Line of credit facility term loan         3 years              
Line of credit facility, description         The proceeds of the term loan are expected to be used for laboratory capital expenditures and will be repaid monthly. The balance of the Line of Credit is available for working capital purposes as a revolving line of credit and has a three-year term. The borrowing limit of the revolving line of credit is the lower of 80% of the Company's eligible accounts receivable (as adjusted by SVB) and the aggregate amount of cash collections with respect to accounts receivable during the three prior calendar months.   The amount that may be borrowed under the Revolving Line is the lower of (i) $3.75 million or (ii) 80% of the Company's eligible accounts receivable (as adjusted by SVB). Revolving Line outstanding amounts incur interest at a rate per annum equal to the Wall Street Journal Prime Rate plus 0.5%. The Company is also required to pay an unused Revolving Line facility fee monthly in arrears in an amount equal to 0.35% per annum of the average unused but available portion of the Revolving Line. The term loan portion of the SVB Loan Agreement has a maturity date of May 2, 2022, and the Revolving Line has a maturity date three years from the effective date, or November 13, 2021          
Line of credit, percentage         0.50%              
Silicon Valley Bank [Member] | Prime Rate [Member]                        
Line of credit, percentage         5.00%   0.50%          
Silicon Valley Bank [Member] | Maximum [Member]                        
Line of credit facility                     $ 4,000,000  
Series B Preferred Stock [Member]                        
Public offering generating net proceeds     $ 19,500,000                  
Sale of common stock     20,000                  
Security Purchase and Exchange Agreement [Member]                        
Line of credit facility                       $ 4,000,000
Equity Distribution Agreement [Member]                        
Public offering generating net proceeds       $ 4,800,000                
ATM Agreement [Member]                        
Public offering generating net proceeds             $ 700,000          
Sale of common stock             178,000          
Centers for Medicare & Medicaid Services [Member] | Subsequent Event [Member]                        
Loans payable $ 2,100,000                      
Proceeds from loans payable 2,100,000                      
Department of Health and Human Services [Member] | Subsequent Event [Member]                        
Loans payable $ 650,000                      
Proceeds from loans payable   $ 650,000                    
Asset Purchase Agreement [Member] | Subsequent Event [Member]                        
Proceeds from loans payable           $ 888,000            
Asset Purchase Agreement [Member] | Subsequent Event [Member] | CGI Bio Pharma [Member]                        
Proceeds from loans payable           $ 888,000